Long Acting Injectables And Cost Discipline Will Transform This Addiction Treatment Leader

Catalysts

About Indivior

Indivior focuses on treatments for opioid use disorder, with SUBLOCADE as its lead long acting injectable therapy.

What are the underlying business or industry changes driving this perspective?

• SUBLOCADE holds roughly 75% share of the U.S. long acting injectable category, and management is concentrating resources on this product. This can support continued net revenue contribution and operating leverage as fixed costs are spread over a focused portfolio.
• Management is targeting deeper penetration of long acting injectables in opioid use disorder, supported by label updates such as rapid induction and alternate injection sites that are resonating with prescribers. This can feed into higher SUBLOCADE volumes and support gross margin levels in the low to mid 80% range.
• The new omnichannel direct to consumer campaign, Move Forward in Recovery, aims to reduce stigma and increase patient awareness of medication assisted treatment. This can drive more patient starts and follow through into higher SUBLOCADE revenue and EBITDA.
• A large portion of the addressable population is treated through Medicaid and commercial plans where SUBLOCADE already has broad coverage. Many commercial patients often face zero out of pocket cost, which can support mix toward more profitable commercial lives and help lift net margins and cash generation.
• The Indivior Action Agenda includes Phase 1, which is focused on simplifying the business, and Phase II, Accelerate, which is set to start in 2026. This plan is expected to reduce nonessential spend by at least US$150 million a year and cap 2026 operating expenses at US$450 million, which directly supports adjusted EBITDA growth and free cash flow.

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more optimistic perspective on Indivior Pharmaceuticals compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
• The bullish analysts are assuming Indivior Pharmaceuticals's revenue will grow by 5.7% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from 26.7% today to 41.5% in 3 years time.
• The bullish analysts expect earnings to reach $651.4 million (and earnings per share of $5.19) by about August 2029, up from $356.0 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $527.3 million.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 10.0x on those 2029 earnings, down from 12.1x today. This future PE is lower than the current PE for the GB Pharmaceuticals industry at 15.6x.
• The bullish analysts expect the number of shares outstanding to decline by 5.41% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• SUBLOCADE currently relies on the U.S. long acting injectable segment of the opioid use disorder market, and management notes that LAI penetration is only about 8%, so if long term adoption of LAIs stalls well below categories like HIV or schizophrenia that have reached 20% to 25%, SUBLOCADE volumes could fall short of bullish expectations, which would pressure revenue and earnings growth.
• The cost base has been reduced through a 32% headcount cut, R&D and medical restructuring, OPVEE promotion discontinuation and Rest of World optimization. If these cuts limit Indivior’s ability to support SUBLOCADE uptake, manage payer relationships or progress pipeline assets, the planned operating expense savings could come at the expense of growth, which would weigh on net revenue and restrict margin expansion.
• Guidance and commentary highlight continued reliance on SUBOXONE Film price stability and relatively slow share decline. If generic competition, payer actions or pricing pressure return over time, that cash flow could fade faster than expected and reduce the funding buffer for SUBLOCADE promotion and R&D, which would affect adjusted EBITDA and free cash flow.
• The company is concentrating resources on a narrow set of geographies, mainly the U.S. plus Australia, Canada, France and Germany, and is streamlining its Rest of World footprint. Any long term regulatory, reimbursement or policy changes that reduce access to medication assisted treatment in these core markets could have an outsized effect on SUBLOCADE prescribing, which would directly reduce revenue and limit earnings growth.
• Management plans to keep 2026 non GAAP operating expenses capped at US$450 million while also considering advancing Phase II assets into Phase III without increasing that budget. If trial costs, commercial investments or inflation in operating costs run higher over several years, Indivior may have to choose between protecting margins and funding growth initiatives, which could constrain net margin expansion and earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Indivior Pharmaceuticals is $53.0, which represents up to two standard deviations above the consensus price target of $49.75. This valuation is based on what can be assumed as the expectations of Indivior Pharmaceuticals's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $53.0, and the most bearish reporting a price target of just $46.0.
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $1.6 billion, earnings will come to $651.4 million, and it would be trading on a PE ratio of 10.0x, assuming you use a discount rate of 7.1%.
• Given the current share price of $36.5, the analyst price target of $53.0 is 31.1% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.